Sarah Weiss, MD
- Medical Oncology
As a native New Jerseyan, it is a privilege to serve on the faculty of the Rutgers Cancer Institute as an Associate Professor of Medicine and the Director of the Melanoma/Cutaneous Oncology Program. I am a medical oncologist with expertise in melanoma and other cutaneous malignancies (merkel cell, basal cell, and squamous cell carcinomas).
I received my undergraduate degree from the Rutgers College Honors Program at Rutgers University and my medical degree from the Albert Einstein College of Medicine, with distinction in Oncology Research. I completed my Internal Medicine residency at Einstein/Montefiore Medical Center and a fellowship in Hematology/Medical Oncology at NYU School of Medicine, where I additionally completed a fourth year of training in the Physician Scientist Training Program to focus on research in melanoma. Prior to joining Rutgers, I was an Assistant Professor of Medicine at Yale Cancer Center where I treated skin cancer patients and designed, conducted, and led clinical trials and translational research centered around advanced melanoma.
At Rutgers Cancer Institute of New Jersey, New Jersey’s only NCI-designated cancer center, I work collaboratively with my colleagues in the Melanoma and Soft Tissue Oncology Program to provide comprehensive and multidisciplinary care for all of our skin cancer patients. I am committed to offering the most personalized and up-to-date treatment for my patients. Our program maintains a diverse portfolio of clinical trials, and I routinely offer patients the opportunity for participation in these clinical trials. My primary research interests are to develop innovative immunotherapeutic strategies to treat advanced skin cancers, particularly for those patients whose cancer has not responded to standard therapies. I aim to better understand why some patients’ tumors are resistant to certain therapies and to develop ways to overcome this resistance.
Melanoma, merkel cell carcinoma, cutaneous squamous cell carcinoma, basal cell carcinoma, advanced skin cancers, immunotherapy, targeted therapy, clinical trials